Supplements

Greater sleep latency is associated with worse inhibitory control in pediatric ALL survivors

In a pilot study of 23 children aged 8-12 who were >6 months post-treatment for acute lymphoblastic leukemia, greater objectively measured sleep latency was associated with worse inhibitory control (r = -0.42, p = 0.046). Total sleep time was positively associated with inhibitory control and attention. The study demonstrated feasibility and acceptability of home EEG-based sleep monitoring in this population.

1 min readUpdated Aug 12, 20260 RCTsView structured evidence →
Evidence Score34/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Greater sleep latency is associated with worse inhibitory control in pediatric ALL survivors The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).

The Claim

Greater sleep latency is associated with worse inhibitory control in pediatric ALL survivors

This conclusion is most relevant to: Children ages 8-12 (M=10 years, SD=1.6; N=23) who were >6 months post-treatment for acute lymphoblastic leukemia.

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • Wearable Sleep Monitoring in Pediatric Acute Lymphoblastic Leukemia: Associations With Subjective Sleep Ratings and Neurocognitive Functioning. (Pediatric blood & cancer, 2026) —

How It Works

The proposed biological pathway:

  • Sleep disturbances are common in pediatric cancer survivors
  • Sleep latency reflects difficulty initiating sleep
  • Prolonged sleep latency may impair prefrontal cortex function
  • Result: Greater sleep latency linked to worse inhibitory control

Who Might Benefit

Evidence fit by population:

  • Children ages 8-12 (M=10 years, SD=1.6; N=23) who were >6 months post-treatment for acute lymphoblastic leukemia

Limitations & Caveats

Important context when interpreting this evidence:

  • Small sample size (N=23) limits generalizability
  • Only two nights of sleep monitoring may not capture typical sleep patterns
  • No control group; single-institution feasibility study without intervention

Frequently Asked Questions

What sleep parameters were measured in this study?

The study measured sleep latency, total sleep time, snoring levels, and overall sleep quality using an EEG-based wearable device (Sleep ProfilerTM) over two consecutive nights at home.

How was neurocognitive functioning assessed?

Neurocognitive testing assessed attention, inhibitory control, working memory, and processing speed after the two nights of sleep monitoring.

What percentage of children had good quality sleep data?

All 23 participants wore the device both nights, and 84% of nights met the threshold for good quality EEG measurement.

Were subjective sleep ratings consistent with objective measurements?

No, 43.5% of subjective parent ratings fell above the threshold for sleep disturbance, while objective measures showed few children meeting recommended sleep quantity and quality thresholds.

References

  1. 1.Ruble K, Northrup R, Nusinov T, Jacobson LA. “Wearable Sleep Monitoring in Pediatric Acute Lymphoblastic Leukemia: Associations With Subjective Sleep Ratings and Neurocognitive Functioning..” Pediatric blood & cancer, 2026. PMID: 42527959 DOI: 10.1002/1545-5017.70476
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.